Nuo and Nord have made an additional investment of 200 million yuan in their strategic production base in Tianjin.

On June 15th, it was announced during the visit of Novo Nordisk's global executive team to China that they will be increasing their investment by 200 million RMB in their strategic production base in Tianjin, to enhance the assembly production capacity of 1.5ml FlexPen injection pens. Upon completion of the project, it will significantly increase the production capacity and supply efficiency of related high-quality products. Since 2003, Novo Nordisk has invested over 17 billion RMB in China.